Author

Ismail Ceylan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

A. ConstantinescuiD· 1 shared Akinchan Kumar· 1 shared Aurélie Cabannes‐HamyiD· 1 shared Axelle BerrouiD· 1 shared Bassam JanjiiD· 1 shared Camille Gillet· 1 shared Delphine Colignon· 1 shared Guillaume MartiniD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. ConstantinescuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Harnessing ALDH1A2 vulnerability in T-cell acute lymphoblastic leukemia

Guillaume P. Andrieu, Lucien Courtois, Mickael Bonnet, Camille Gillet, Mélodie Queri, Mélanie Féroul, Ludovic Lhermitte, Patrick Villarèse, Aurélie Cabannes‐Hamy, Philippe H. Rousselot, Mileydis Perez, Ismail Ceylan, Salvatore Spicuglia, Vahid Asnafi

This study identifies ALDH1A2 as a therapeutic target in T-ALL, showing its essential role in leukemic cell survival and demonstrating potent anti-leukemic activity with Dimate inhibition.

bioRxiv · Mar 11, 2025 · PreprintCancer Biology

ALDH1 subtype-specific inhibitor targets key cancerous epithelial cell populations in aggressive subtypes of breast cancer

Raquel Pequerul, A. Constantinescu, Bassam Janji, Akinchan Kumar, Xavier Parés, Òscar Palacios, Delphine Colignon, Axelle Berrou, Guy Fournet, Paul BERCHARD, Guillaume Martin, Ismail Ceylan, Rocio Rebollido-Ríos, Jaume Farrés, Mileidys Perez-Alea

This study identifies ALDH1A3 as a therapeutic target in aggressive breast cancers and develops ABD0171, a selective inhibitor showing antitumor and antimetastatic effects.

bioRxiv · Oct 18, 2024 · PreprintCancer Biology